PFIZER LIMITED (PFIZER) AI Stock Analysis

• Market Cap: ₹232.70B
• Dividend Yield: 0.69%
• Average Volume (3M): 2.39K
• Price to Earnings (P/E): 27.3
• Beta (1Y): 0.61
• Revenue Growth: 6.13%
• EPS Growth: 35.83%
• Country: IN
• Employees: 1,721
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 40.40
• Shares Outstanding: 45,747,730
• 10 Day Avg. Volume: 3,328
• 30 Day Avg. Volume: 2,388
• PEG Ratio: 0.61
• Price to Book (P/B): 4.38
• Price to Sales (P/S): 8.09
• P/FCF Ratio: 29.23
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹6,030.00
• Price Target Upside: 23.38% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 162.93
• Revenue Forecast (FY): ₹24.28B

• Rating: 69 Neutral
• Price Target: ₹5,031.00 ▲(2.94% Upside)
• Action: Reiterated Date: 11/01/25
• Date: Action: Reiterated 11/01/25

PFIZER LIMITED's strong financial performance is the most significant factor, supported by robust profitability and cash flow management. However, the stock's valuation appears high, and technical indicators suggest potential short-term weakness. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Balance Sheet Health

Extremely low leverage and a high equity ratio provide durable financial flexibility, enabling sustained R&D investment, dividend support, and M&A optionality. A strong ROE indicates efficient capital use, which helps the business withstand industry cycles and fund long-term strategic initiatives.

Cash Generation

Very strong free cash flow conversion and large FCF growth underpin sustainable funding for pipelines, capital allocation, and shareholder returns. Reliable cash conversion reduces refinancing risk and supports durable operating plans even if topline growth slows.

High Profitability/Margins

Consistently high gross and operating margins indicate durable pricing power and operational efficiency. Strong profitability provides buffer versus pricing pressure, funds reinvestment in product development, and sustains long-term returns even in competitive pharmaceutical markets.

Negative Factors

Revenue Volatility

Volatile top-line performance reduces predictability of future cash flows and makes long-term planning harder for a product-driven pharma business. It can reflect portfolio concentration, timing of product cycles, or one-off items that impair steady organic growth over multiple quarters.

Limited Entity Disclosure

Lack of clear disclosure about the legal entity's exact operating scope complicates assessment of revenue drivers, regulatory exposures, and operational risks. This structural opacity can hinder investor understanding of sustainable cash flows and long-term strategy execution.

Moderate Top-line Growth

Single-digit revenue growth suggests limited organic expansion relative to high-margin profile, necessitating continued reliance on margin improvements or cash deployment to drive returns. Sustained low growth could pressure long-term EPS upside absent major product launches or acquisitions.

PFIZER LIMITED Business Overview & Revenue Model

Company Description

Pfizer Limited manufactures, markets, trades in, and exports pharmaceutical products in India and internationally. The company offers its products in various therapeutic areas, including neuro/central nervous system, hormones, cardiovascular, hemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastro intestinal, vaccines, respiratory, and vitamins/minerals/nutrients. It sells its products through a network of independent distributors primarily under various brand names. The company was incorporated in 1950 and is headquartered in Mumbai, India.

How the Company Makes Money

Pfizer generates revenue primarily through the sale of its pharmaceutical products, which includes prescription medications and vaccines. The company's revenue model is built on a combination of direct sales to healthcare providers and institutions, as well as sales through partnerships and collaborations with other pharmaceutical companies and healthcare organizations. Key revenue streams include established blockbuster drugs, new product launches, and ongoing sales of its COVID-19 vaccine. Additionally, Pfizer benefits from licensing agreements and collaborations that allow it to share research and development costs, expand market access, and enhance its product offerings. Strategic partnerships, including those with government entities for vaccine distribution and joint ventures for drug development, also contribute significantly to its earnings.

PFIZER LIMITED Financial Statement Overview

Summary

PFIZER LIMITED exhibits strong financial performance with high profitability margins, a robust balance sheet with low leverage, and excellent cash flow management. The company's consistent improvement in key financial metrics underscores its competitive standing in the industry.

Income Statement

PFIZER LIMITED has demonstrated strong profitability with a consistent gross profit margin above 60% and an increasing net profit margin, reaching 33.6% in the latest period. The company has shown a healthy EBIT margin of 48.2% and an EBITDA margin of 32.4% for the most recent year. Revenue growth has been somewhat volatile, but there is a positive growth trajectory from the previous year, indicating resilience in the market.

Balance Sheet

The company's balance sheet is robust, with a low debt-to-equity ratio of 0.03, suggesting limited leverage and a strong equity cushion. The return on equity is impressive at 18.2%, indicating efficient use of equity. Additionally, the equity ratio stands at 85.9%, showing a strong capital structure with high asset backing.

Cash Flow

PFIZER LIMITED exhibits a strong cash flow position. With a significant increase in free cash flow, the free cash flow growth rate is 165.5%. The operating cash flow to net income ratio is favorable at 0.86, and the free cash flow to net income ratio is 0.82, suggesting that the company efficiently converts profits into cash.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	23.22B	22.81B	21.93B	24.25B	26.11B	22.40B
Gross Profit	14.95B	14.66B	13.95B	15.47B	16.58B	14.38B
EBITDA	7.46B	7.05B	5.99B	7.70B	7.88B	6.70B
Net Income	8.09B	7.68B	5.51B	6.24B	6.13B	4.98B
Balance Sheet
Total Assets	0.00	49.11B	42.29B	40.01B	39.01B	32.66B
Cash, Cash Equivalents and Short-Term Investments	27.83B	28.01B	20.27B	18.40B	16.33B	10.98B
Total Debt	0.00	1.08B	945.40M	1.34B	1.67B	1.06B
Total Liabilities	-42.17B	6.94B	6.33B	7.93B	10.36B	8.73B
Stockholders Equity	42.17B	42.17B	35.96B	32.07B	28.64B	23.93B
Cash Flow
Free Cash Flow	0.00	6.32B	2.38B	2.91B	6.52B	4.10B
Operating Cash Flow	0.00	6.60B	2.57B	3.56B	6.67B	4.27B
Investing Cash Flow	0.00	-713.40M	-713.40M	-360.50M	-5.75B	-4.69B
Financing Cash Flow	0.00	-2.05B	-2.05B	-3.46B	-1.81B	-15.71B

PFIZER LIMITED Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4887.30
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PFIZER, the sentiment is Positive. The current price of 4887.3 is below the 20-day moving average (MA) of 4921.47, above the 50-day MA of 4879.69, and below the 200-day MA of 5141.70, indicating a neutral trend. The MACD of 82.73 indicates Negative momentum. The RSI at 57.52 is Neutral, neither overbought nor oversold. The STOCH value of 66.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:PFIZER.

PFIZER LIMITED Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IPCALAB	74 Outperform	₹386.41B	42.48	―	0.28%	9.66%	25.79%
ALKEM	72 Outperform	₹657.18B	27.74	―	0.80%	9.32%	11.25%
ASTRAZEN	70 Outperform	₹219.78B	109.41	―	0.35%	35.14%	143.11%
PFIZER	69 Neutral	₹232.70B	27.26	―	0.69%	6.13%	35.83%
GLENMARK	53 Neutral	₹581.88B	54.63	―	0.24%	30.27%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

PFIZER LIMITED Corporate Events

Exchange Seeks Clarification from Pfizer Limited on Q2 FY2025 Financial Results

The stock exchange has requested clarification from Pfizer Limited regarding its financial results for the quarter ended 30 September 2025, specifically in relation to compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company’s response is still awaited, leaving investors and other stakeholders without further detail on the nature of the exchange’s queries or any potential implications for Pfizer Limited’s financial reporting and regulatory compliance until the clarification is provided.

Pfizer Limited to Appeal GST Demand Order of Rs 8.79 Crore

Pfizer Limited has disclosed that it received an order from the Additional Commissioner of GST & CX, Kolkata, following a GST audit for West Bengal covering financial years 2018-19 to 2022-23, raising a tax demand of Rs 4.40 crore and an equivalent penalty, totalling about Rs 8.79 crore plus interest, over alleged incorrect availment of input tax credit. The company maintains that the demand is not maintainable, plans to appeal the order, and has stated that the proceedings are not expected to have any material impact on its financials, operations or business activities, suggesting limited near-term implications for shareholders and other stakeholders.